Clinical characteristics and laboratory profiles of hospitalized patients with COVID-19 with confirmed HIT and patients with negative confirmatory tests
| Variables . | Patients with confirmed HIT (N = 19) . | Patients with negative confirmatory tests (N = 26) . |
|---|---|---|
| Age (y) | 62.0 (50.0, 64.0)* | 62 (50, 68.75)* |
| Sex (male; female) | 14 (74%); 5 (26%) | 21 (81%); 5 (19%) |
| Type of heparins (UFH; LMWH) | 17 (63%); 10 (37%) | 15 (43%), 16 (46%) [4 N/A (11%)] |
| Intensity of anticoagulants (prophylactic; therapeutic) | 5 (26.3%); 13 (68.4%) [1 N/A (5.3%)] | 9 (34.6%%); 9 (34.6%); [8 N/A (30.8%)] |
| Duration of heparin to HIT diagnosis (d) | 13.5 (10.75, 16.25)* | 11 (6, 21)* |
| Initial platelet counts (×109/L) | 223 (160.5, 297)* | 209 (145.5, 247.5)* |
| Nadir platelet counts (×109/L) | 56 (37, 73)* | 59 (37.5, 91.75)* |
| Thrombosis after heparin administration | 12 (63%) | 16 (61.5%) |
| 4T score | 5.5 (4, 6)* | 5 (4, 6)* |
| Variables . | Patients with confirmed HIT (N = 19) . | Patients with negative confirmatory tests (N = 26) . |
|---|---|---|
| Age (y) | 62.0 (50.0, 64.0)* | 62 (50, 68.75)* |
| Sex (male; female) | 14 (74%); 5 (26%) | 21 (81%); 5 (19%) |
| Type of heparins (UFH; LMWH) | 17 (63%); 10 (37%) | 15 (43%), 16 (46%) [4 N/A (11%)] |
| Intensity of anticoagulants (prophylactic; therapeutic) | 5 (26.3%); 13 (68.4%) [1 N/A (5.3%)] | 9 (34.6%%); 9 (34.6%); [8 N/A (30.8%)] |
| Duration of heparin to HIT diagnosis (d) | 13.5 (10.75, 16.25)* | 11 (6, 21)* |
| Initial platelet counts (×109/L) | 223 (160.5, 297)* | 209 (145.5, 247.5)* |
| Nadir platelet counts (×109/L) | 56 (37, 73)* | 59 (37.5, 91.75)* |
| Thrombosis after heparin administration | 12 (63%) | 16 (61.5%) |
| 4T score | 5.5 (4, 6)* | 5 (4, 6)* |
N/A, not available.
Median (interquartile range).